Big Pharma Split Corp.
PRM.TO
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 2.58M | 1.41M | 236.80K | 1.10M | 1.99M |
| Total Revenue | 2.58M | 1.41M | 236.80K | 1.10M | 1.99M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.58M | 1.41M | 236.80K | 1.10M | 1.99M |
| SG&A Expenses | 443.10K | 437.10K | 428.70K | 458.90K | 493.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 84.00K | 81.30K | 78.10K | 79.40K | 81.30K |
| Total Operating Expenses | 527.20K | 518.50K | 506.90K | 538.50K | 574.70K |
| Operating Income | 2.05M | 895.30K | -270.10K | 556.70K | 1.42M |
| Income Before Tax | 854.80K | 190.80K | -478.60K | -328.20K | -172.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.85 | 0.19 | -0.48 | -0.33 | -0.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 854.80K | 190.80K | -478.60K | -328.20K | -172.40K |
| EBIT | 2.05M | 895.30K | -270.10K | 556.70K | 1.42M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.74 | 0.18 | -0.39 | -0.28 | -0.17 |
| Normalized Basic EPS | 0.46 | 0.11 | -0.24 | -0.18 | -0.11 |
| EPS Diluted | 0.74 | 0.18 | -0.39 | -0.28 | -0.17 |
| Normalized Diluted EPS | 0.46 | 0.11 | -0.24 | -0.18 | -0.11 |
| Average Basic Shares Outstanding | 4.70M | 4.78M | 4.87M | 5.19M | 5.52M |
| Average Diluted Shares Outstanding | 4.70M | 4.78M | 4.87M | 5.19M | 5.52M |
| Dividend Per Share | 0.91 | 0.92 | 0.92 | 0.92 | 0.92 |
| Payout Ratio | 177.14% | 808.60% | -326.51% | -512.92% | -1,054.76% |
